A comprehensive hepatitis C viral kinetic model explaining cure (Q42997057)

12 November 2017

A comprehensive hepatitis C viral kinetic model explaining cure (English)

1 reference

12 November 2017

1 reference

E Snoeck

1

1 reference

12 November 2017

P Chanu

2

1 reference

12 November 2017

M Lavielle

3

1 reference

12 November 2017

P Jacqmin

4

1 reference

12 November 2017

E N Jonsson

5

1 reference

12 November 2017

K Jorga

6

1 reference

12 November 2017

T Goggin

7

1 reference

12 November 2017

J Grippo

8

1 reference

12 November 2017

N L Jumbe

9

1 reference

12 November 2017

N Frey

10

1 reference

12 November 2017

language of work or name

English

0 references

publication date

12 May 2010

1 reference

Clinical Pharmacology & Therapeutics

12 November 2017

1 reference

12 November 2017

87

1 reference

12 November 2017

6

1 reference

12 November 2017

706-713

1 reference

Diagnosis, management, and treatment of hepatitis C

12 November 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

New kinetic models for the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Viral dynamics in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

The kinetics of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Viral kinetics of hepatitis C: new insights and remaining limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Viral kinetics in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

HIV-1 infection and low steady state viral loads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Liver regeneration and surgical outcome in donors of right-lobe liver grafts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Diagnosing model diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

American Gastroenterological Association technical review on the management of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Detection of HCV RNA in saliva, urine, seminal fluid, and ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Diagnostic tests. 1: Sensitivity and specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

inferred from DOI database lookup

7 January 2021

based on heuristic

Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.35

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2010.35

1 reference

12 November 2017

1 reference